Preferred Label : Boditrectinib;
NCIt synonyms : TRK Inhibitor NOV1601; Pan-TRK Inhibitor NOV1601;
NCIt definition : An orally bioavailable, selective pan-tropomyosin-related-kinase (tyrosine receptor
kinase; TRK) inhibitor, with potential antineoplastic activity. Upon oral administration,
boditrectinib specifically targets and binds to TRK, TRK mutations and fusion proteins
containing sequences from neurotrophic tyrosine receptor kinase (NTRK) types 1 (NTRK1;
TrkA), 2 (NTRK2; TrkB), and 3 (NTRK3; TrkC). This inhibits neurotrophin-TRK interaction
and TRK activation, thereby preventing the activation of downstream signaling pathways
and resulting in both the induction of cellular apoptosis and the inhibition of cell
growth in tumors that overexpress TRK and/or express NTRK fusion proteins. TRK, a
family of receptor tyrosine kinases (RTKs) activated by neurotrophins, is encoded
by NTRK family genes. The expression of either mutated forms of, or fusion proteins
involving, NTRK family members results in uncontrolled TRK signaling, which plays
an important role in tumor cell growth, survival, invasion and treatment resistance.;
UNII : M359MC7QGE;
CAS number : 1940165-80-9; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 1940165-80-9
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Molecule name : CHC 2014; NOV-1601; NOV 1601; CHC-2014; AUM-601; HL5101;
NCI Metathesaurus CUI : CL1406349;
Origin ID : C172394;
UMLS CUI : C5417918;
Semantic type(s)
- concept_is_in_subset
